Edwards Lifesciences Aktie
| 70,00USD | 0,46USD | 0,66% |
WKN: 936853 / ISIN: US28176E1082
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 98,30 |
| The Vanguard Group, Inc. | 10,39 |
| Vanguard Group, Inc. (Subfiler) | 9,95 |
| Wellington Management Co. LLP | 5,23 |
| Wellington Management Co. LLP (Wellington Breakout) | 4,74 |
| State Street Corp. | 4,36 |
| BlackRock Fund Advisors | 3,27 |
| Vanguard Total Stock Market ETF | 3,17 |
| Vanguard 500 Index Fund | 2,62 |
| Geode Capital Management LLC | 2,24 |
| BlackRock Institutional Trust Co. NA | 2,18 |
| Walter Scott & Partners Ltd. | 2,06 |
| Vanguard Health Care Fund | 1,88 |
| Fisher Asset Management LLC | 1,51 |
| Norges Bank (13F) | 1,42 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 13 900 | 14 900 | 15 700 | 17 300 | 19 800 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,31 | 0,29 | 0,33 | 0,31 | 0,30 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 2 984 | 3 091 | 3 181 | 3 096 | 4 036 |
| Summe Anlagevermögen | 3 504 | 4 146 | 5 322 | 5 197 | 5 328 |
| Summe Aktiva | 6 488 | 7 237 | 8 503 | 8 293 | 9 363 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 679 | 695 | 690 | 691 | 695 |
| Summe Fremdkapital | 2 340 | 2 663 | 2 667 | 2 486 | 2 644 |
| Summe Eigenkapital | 4 148 | 4 574 | 5 836 | 5 807 | 6 719 |
| Summe Passiva | 6 488 | 7 237 | 8 503 | 8 293 | 9 363 |
Adresse
| 1 Edwards Way, 92614 Irvine | |
| Telefon | +1 (949) 250-2500 |
| Internet | http://www.edwards.com |
Management
|
Andrew M. Dahl
Chief Accounting Officer |
|
Arnold A. Pinkston
Vice President & General Counsel |
|
Bernard J. Zovighian
President, Chief Executive Officer & Director |
|
Catherine M. Szyman
Vice President & General Manager-Critical Care |
|
Christine Z. McCauley
Vice President-Human Resources |
|
Daniel J. Lippis
VP-Japan, Greater China & Asia Pacific |
|
Daveen Chopra
VP-Transcatheter Mitral & Tricuspid Therapies |
|
David T. Feinberg
Director |
|
Donald E. Bobo
Vice President-Strategy & Corporate Development |
|
Gary I. Sorsher
SVP-Quality & Regulatory Compliance |
|
Jean-Luc Lemercier
Corporate Vice President-EMEA |
|
Kieran Thomas Gallahue
Independent Director |
|
Larry L. Wood
Vice President |
|
Leslie C. Davis
Independent Director |
|
Leslie Stone Heisz
Independent Director |
|
Linda J. Park
Secretary, Senior VP & Associate General Counsel |
|
Mark A. Wilterding
Investor Contact |
|
Markowitz Wayne
SVP-Surgical Structural Heart & General Manager |
|
Nicholas J. Valeriani
Chairman |
|
Paul A. LaViolette
Independent Director |
|
Ramona Sequeira
Independent Director |
|
Scott B. Ullem
Chief Financial Officer & Vice President |
|
Steven R. Loranger
Independent Director |
|
Tammy Perry
Senior Director-Corporate Sustainability |
|
Tim Patz
SVP-Japan Sales & Marketing |
|
Todd J. Brinton
Chief Scientific Officer & VP-Advanced Technology |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
